BioXcel Therapeutics (BTAI) Share-based Compensation (2017 - 2026)

BioXcel Therapeutics' Share-based Compensation history runs 10 years deep, the most recent figure standing at $435000.0 for Q1 2026.

• In Q1 2026, Share-based Compensation rose 141.67% year-over-year to $435000.0; the TTM figure through Mar 2026 stood at $2.6 million (down 11.68% YoY), while the FY2025 annual figure was $2.8 million, down 55.05% from the prior year.
• Share-based Compensation was $435000.0 for Q1 2026 at BioXcel Therapeutics, down from $450000.0 in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $6.1 million in Q2 2023 to a low of -$199000.0 in Q4 2024.
• Historically, Share-based Compensation has averaged $2.6 million across 5 years, with a median of $3.4 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation surged 371.4% in 2022, then sank 105.53% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $4.5 million in 2022, then dropped by 20.85% to $3.6 million in 2023, then plunged by 105.53% to -$199000.0 in 2024, then surged by 326.13% to $450000.0 in 2025, then retreated by 3.33% to $435000.0 in 2026.
• The last three Share-based Compensation figures came in at $435000.0 (Q1 2026), $450000.0 (Q4 2025), and $581000.0 (Q3 2025), per Business Quant data.